碩貝德(300322.SZ)擬吸收合併全資子公司明業光電
格隆匯 6 月 29日丨碩貝德(300322.SZ)公佈,為進一步優化公司管理架構,提高運營效率,降低管理成本,公司擬吸收合併全資子公司廣東明業光電有限公司(“明業光電”)。吸收合併完成後,明業光電的獨立法人資格將被註銷,其全部資產、債權債務及其他一切權力和義務均由公司依法承繼。
公司此次吸收合併明業光電,有利於公司管理架構的進一步優化,降低管理成本,提高運營效率,符合公司發展戰略。明業光電為公司的全資子公司,其財務報表已納入公司的合併報表範圍,此次吸收合併不會對公司財務狀況產生實質影響,不會影響公司業務發展和持續盈利能力,符合公司及全體股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.